People · Operator
Named in public records as an officer, director or promoter · active 2011–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Protagenic Therapeutics, Inc.\new | — | Biotechnology | Series A | $9.4M | $24.2M | 2011 |
Raymond Musci at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Raymond Musci on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Dyne | 1 | 6 |
| Robert B. Stein | 1 | 5 |
| Lawrence Burstein | 1 | 3 |
| Garo H. Armen | 1 | 3 |
| Alexander K. Arrow | 1 | 2 |
| Thomas Plotts | 1 | 1 |
| Stuart Goldfarb | 1 | 1 |
| Jerome Chazen | 1 | 1 |
| Gregory H. Ekizian | 1 | 1 |
| Khalil B. Barrage | 1 | 1 |
| Joshua K. Silverman | 1 | 1 |
| Robert H. Ziroyan | 1 | 1 |
| Joshua B Silverman | 1 | 1 |
| Brian J Corvese | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.